
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp has demonstrated substantial growth in the sales of its HEPLISAV-B product, reporting a 39% year-over-year increase in 4Q24 sales and a 26% increase for the full fiscal year 2024, with total sales reaching $268.4 million. The company's market share for HEPLISAV-B has expanded to approximately 44% by the end of 2024, with future sales anticipated to grow due to strong penetration in the eligible adult market and re-vaccination practices, projecting net revenue guidance of $305 million to $325 million for FY25. Moreover, Dynavax's advocacy for a $400 million share repurchase program reinforces its confidence in sustaining long-term market opportunities and achieving a dominant share within the anticipated $900 million hepatitis B vaccination market by 2030.
Bears say
Dynavax Technologies Corp faces significant challenges that contribute to a negative outlook on its stock. The company's future candidates in clinical development may fail to meet efficacy endpoints, coupled with market conditions and competitive pressures that could hinder successful commercialization. Additionally, Dynavax's financial history is marked by losses, highlighting the lack of a sustainable profitability track record, which exacerbates concerns regarding the ability to effectively develop and launch its pipeline candidates.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares